Gabapentin Capsule
Product Images NDC 0480-3496

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0480-3496). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation Of Cockcroft And Gault (Image 1)

An illustration showing the creatinine clearance (CLCr) formula, which calculates renal function using age in years, weight in kilograms, serum creatinine in mg/dL, with a multiplication factor of 0.85 applied for female patients.*

FDA Label Image

1 (Image 2)

Chemical structure of the active ingredient Gabapentin as depicted in the image, showing a cyclohexane ring with two substituents: a CH2NH2 group and a CH2CO2H group.*

FDA Label Image

Figure 1 (Image 3)

A line graph comparing mean pain scores over an 8-week period between placebo and gabapentin 3600 mg/day. The x-axis indicates weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. The chart highlights a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2 (Image 4)

A line graph showing mean pain scores over a 7-week period for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a greater reduction in mean pain score compared to placebo.*

FDA Label Image

Figure 3 (Image 5)

Bar chart comparing outcomes of two studies involving gabapentin (GBP) labeled as GBP 3600, GBP 1800, and GBP 2400, versus placebo (PBO). Study 1 shows 12% for placebo and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance levels are indicated with p-values <0.01 and <0.001.*

FDA Label Image

Figure 4 (Image 6)

A scatter plot chart showing the percentage difference on the y-axis and daily dose in mg on the x-axis for gabapentin. Data points are plotted from three studies labeled a, b, and c, with daily doses ranging approximately from 600 to 1800 mg and difference percentages from about 2% to 20%. Each study is represented by different symbols and shading as indicated in the legend on the right.*

FDA Label Image

100 mg, 500s (Image 7)

Label for Gabapentin Capsules USP 100 mg, containing 500 capsules. The label includes dosing and storage instructions, pharmacist dispensing guidance, and manufacturer details showing production by Watson Pharma Private Limited in India and distribution by Teva Pharmaceuticals, Inc. The label features the NDC 0480-3494-05 and a barcode on the right side.*

FDA Label Image

300 mg, 500s (Image 8)

Label for Gabapentin Capsules USP 300 mg, a pharmaceutical product by Teva Pharmaceuticals, Inc. The label indicates the package contains 500 capsules, with instructions for pharmacists to dispense the accompanying medication guide. Storage and dosage instructions are noted, along with manufacturer details (Watson Pharma Private Limited, India). The label includes an NDC number and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.